Aktis Oncology Inc's Corporate Customers have recorded a rise in their cost of revenue by 21.69 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -13.82 %. During the corresponding time, Aktis Oncology Inc recorded a revenue increase by 123.01 % year on year, While revenue at the Aktis Oncology Inc 's corporate clients recorded rose by 20.59 % year on year, sequentially revenue fell by -7.47 %.
Aktis Oncology Inc's Customers have recorded a rise in their cost of revenue by 21.69 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -13.82 %, for the same period Aktis Oncology Inc recorded revenue increase by 123.01 % year on year,
In a bold move poised to reshape its future, Akoustis Technologies Inc. (AKTS) has announced its intention to pursue a strategic sale through a voluntary Chapter 11 process. This decision comes on the heels of a final judgment that confirmed alleged infringement by Qorvo, underscoring the urgent need for Akoustis to ensure its business is sold free of such encumbrances. The company remains committed to maintaining full business continuity as it works to deliver next-generation BAW (Bulk Acoustic Wave) high-band RF filters to its global clientele, providing reassurance in turbulent waters. Financial Performance Amidst Market ChallengesTurning to recent figures, Akoustis s corporate clients reported a modest y...
In a significant corporate shift, Akoustis Technologies Inc. publicly announced a leadership transition on August 8, 2024. This change comes at a time when the company is reviewing its operational performance amid an environment of fluctuating revenue and expenditure trends across its corporate customer base.Recent financial analyses indicate that Akoustis Technologies corporate customers experienced a year-on-year increase in their cost of revenue by 0.39% for the fourth quarter of 2023. In contrast, a sequential analysis reveals a more concerning growth of 18.98% in costs. These figures draw attention to the complexities surrounding a nuanced revenue landscape. During the same period, Akoustis itself repo...
Quarter 3 Financials Indicates Positive Growth for Akoustis Technologies Amidst Strong Performance by Corporate Customers On May 13, 2024, Akoustis Technologies, Inc., an integrated device manufacturer of patented bulk acoustic wave (BAW) high-band RF filters for wireless applications, will webcast its Q3FY24 results. The webcast, scheduled for 8:00 am ET, will provide updates from the organization and offer a question-and-answer session from the company s management, offering considerable insight into the company s performance.The latest report on Akoustis’s corporate customers paints an optimistic picture. The cost of revenue for the fourth quarter of 2023 remarkably increased by 0.48% on a yearly basis,...
Sources:
Aktis Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aktis Oncology Inc’s corporate clients.
For your research, we’ve provided 9 tables on Aktis Oncology Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1599.01 %
8.67 % 